

## Diagnosing TCC - has the cystoscope had its day?

Poster Session 59

Monday, 14 March  
08:45 - 10:15

**Location:** Room Stockholm (Hall B2, level 0)

**Chairs:** R.T. Bryan, Birmingham (GB)  
A. Miernik, Freiburg (DE)  
L-P. Xie, Hangzhou (CN)

**Aims and objectives of this presentation**

Understand the potential of innovations in endoscopy and urine-based diagnostics.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 738 **The feasibility and safety evaluation of the pressure monitored air cystoscopy during active hematuria**  
By: Yu E., Yao L., Wang Y., Yu W., Zhang Q., Wu S., Zhang X., He Z., Zhou L., Jin J.  
**Institutes:** Peking University First Hospital, Dept. of Urology, Beijing, China
- 739 **Comparison of white light, photodynamic diagnosis (PDD) and narrow band imaging (NBI) in detection of flat dysplasia and CIS at transurethral resection of the bladder – the DaBlCa-8 study**  
By: Drejer D.<sup>1</sup>, Beji S.<sup>2</sup>, Lam G.W.<sup>2</sup>, Jensen J.B.<sup>1</sup>  
**Institutes:**<sup>1</sup>Aarhus University Hospital, Dept. of Urology, Aarhus, Denmark, <sup>2</sup>Herlev Hospital, Dept. of Urology, Herlev, Denmark
- 740 **A new compound for photodynamic diagnosis of non-muscle invasive bladder cancer – results of a multi-centre phase 2 study with PVP-Hypericin**  
By: Straub M.<sup>1</sup>, Steiner R.<sup>2</sup>, Schiefelbein F.<sup>3</sup>, Garlonta V.<sup>4</sup>, Deger S.<sup>5</sup>, Lusuardi L.<sup>6</sup>, Von Pokrzywnitzki W.<sup>7</sup>, Knüchel R.<sup>8</sup>, Schmidbauer J.<sup>9</sup>  
**Institutes:**<sup>1</sup>Klinikum Rechts der Isar der Technischen Universität Muenchen, Dept. of Urology, Munich, Germany, <sup>2</sup>Sindelfingen-Böblingen Medical Centre, Dept. of Urology, Sindelfingen, Germany, <sup>3</sup>Missionsaerztliche Klinik, Dept. of Urology, Würzburg, Germany, <sup>4</sup>Community Hospital Karlsruhe, Dept. of Urology, Karlsruhe, Germany, <sup>5</sup>Paracelsus Krankenhaus Ruit, Dept. of Urology, Ruit, Germany, <sup>6</sup>Paracelsus Medical University, Dept. of Urology, Salzburg, Austria, <sup>7</sup>Vivantes Klinikum Am Urban, Dept. of Urology, Berlin, Germany, <sup>8</sup>University Hospital RWTH, Dept. of Pathology, Aachen, Germany, <sup>9</sup>Medical University of Vienna, Vienna General Hospital, Dept. of Urology, Vienna, Austria
- 741 **Does hexaminolevulinate detect chromosomal aberrations in the false-positive bladder biopsies?**  
By: D'Andrea D.<sup>1</sup>, Martini T.<sup>2</sup>, Mian C.<sup>3</sup>, Palermo S.M.<sup>1</sup>, Comploj E.<sup>1</sup>, Pycha A.<sup>1</sup>  
**Institutes:**<sup>1</sup>General Hospital of Bolzano, Dept. of Urology, Bolzano, Italy, <sup>2</sup>Ulm University Medical Center, Dept. of Urology, Ulm, Germany, <sup>3</sup>General Hospital of Bolzano, Dept. of Pathology, Bolzano, Italy
- 742 **Urothelial tumor and dual band imaging: New concept in confocal laser endomicroscopy**  
By: Bonnal J.L.<sup>1</sup>, Yakoubi R.<sup>1</sup>, Rock A.<sup>1</sup>, El Maadarani K.<sup>1</sup>, Marien A.<sup>1</sup>, Mauroy B.<sup>1</sup>, Gosset P.<sup>2</sup>  
**Institutes:**<sup>1</sup>Hôpital Saint-Philibert, Dept. of Urology, Lomme Cedex, France, <sup>2</sup>Hôpital Saint-Vincent, Dept. of Anatomopathology, Lille Cedex, France
- 743 **Measuring the depth of tumor invasion may have greater prognostic value than AJCC/UICC staging of bladder cancer**  
By: Nishikimi T.<sup>1</sup>, Tsuzuku T.<sup>2</sup>, Mori Y.<sup>3</sup>, Kashiwagi Y.<sup>4</sup>, Sassa N.<sup>5</sup>, Kimura T.<sup>6</sup>, Fukatsu A.<sup>7</sup>, Tanaka K.<sup>8</sup>, Hattori R.<sup>9</sup>, Takahashi S.<sup>3</sup>, Gotoh M.<sup>5</sup>

**Institutes:**<sup>1</sup>Nagoya Daini Red Cross Hospital, Dept. of Urology, Nagoya, Japan, <sup>2</sup>Nagoya Daini Red Cross Hospital, Dept. of Pathology, Nagoya, Japan, <sup>3</sup>Nagoya City University, Dept. of Pathology, Nagoya, Japan, <sup>4</sup>Okazaki Municipal Hospital, Dept. of Urology, Okazaki, Japan, <sup>5</sup>Nagoya University, Dept. of Urology, Nagoya, Japan, <sup>6</sup>JCHO, Cyukyo Hospital, Dept. of Urology, Nagoya, Japan, <sup>7</sup>Komaki Municipal Hospital, Dept. of Urology, Komaki, Japan, <sup>8</sup>Komaki Municipal Hospital, Dept. of Urology, Kariya, Japan, <sup>9</sup>Nagoya Daiichi Red Cross Hospital, Dept. of Urology, Nagoya, Japan

744

**Indolent clinical outcomes of carcinoma in situ-associated pTa bladder tumour after bacillus Calmette-Guérine: Need for a new classification of carcinoma in situ**

**By:** Kim S.J.<sup>1</sup>, Hong S.<sup>2</sup>, Kim H.J.<sup>2</sup>, You D.<sup>1</sup>, Jeong I.G.<sup>1</sup>, Song C.<sup>1</sup>, Hong B.S.<sup>1</sup>, Kim C.S.<sup>1</sup>, Ahn H.<sup>1</sup>, Hong J.H.<sup>1</sup>

**Institutes:**<sup>1</sup>Asan Medical Center, Dept. of Urology, Seoul, South Korea, <sup>2</sup>Dankook University College of Medicine, Dept. of Urology, Cheonan, South Korea

745

**Prognostic performance of different pathological grading schemes in non-muscle invasive transitional-cell carcinoma**

**By:** Nabebina T.<sup>2</sup>, Rolevich A.<sup>1</sup>, Dubrowski A.<sup>2</sup>, Polyakov S.<sup>1</sup>, Krasny S.<sup>1</sup>

**Institutes:**<sup>1</sup>N.N.Alexandrov National Cancer Centre, Dept. of Urology, Minsk, Belarus, <sup>2</sup>N.N.Alexandrov National Cancer Centre, Dept. of Pathology, Minsk, Belarus

746

**Molecular tumour grading of non muscle invasive bladder cancer based on whole transcriptome analysis**

**By:** Shen J.<sup>2</sup>, Noon A.<sup>3</sup>, Aguiar Cabeza E.<sup>2</sup>, Kuk C.<sup>4</sup>, Ilczynski C.<sup>5</sup>, Ni R.<sup>5</sup>, Sukhu B.<sup>5</sup>, Chan K.<sup>2</sup>, Gunaratne A.<sup>2</sup>, Erlich A.<sup>4</sup>, Cremer C.<sup>6</sup>, Morris Q.<sup>6</sup>, Barbosa-Morais N.<sup>6</sup>, Roupert M.<sup>9</sup>, Compérat E.<sup>10</sup>, Sweet J.<sup>8</sup>, Fleshner N.<sup>7</sup>, Kulkarni G.<sup>7</sup>, Blencowe B.<sup>6</sup>, Azad A.<sup>5</sup>, Van Der Kwast T.<sup>8</sup>, Zlotta A.R.<sup>1</sup>, Wrana J.<sup>2</sup>

**Institutes:**<sup>1</sup>Mount Sinai Hospital & Princess Margaret Cancer Centre, Dept. of Urology, Toronto, Canada, <sup>2</sup>Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada, <sup>3</sup>University of Sheffield, Dept. of Urology, Sheffield, United Kingdom, <sup>4</sup>Mount Sinai Hospital, Dept. of Urology, Toronto, Canada, <sup>5</sup>Mount Sinai Hospital, Dept. of Pathology and Laboratory Medicine, Toronto, Canada, <sup>6</sup>University of Toronto, Terrence Donnelly Centre for Cellular and Biomolecular Research, Toronto, Canada, <sup>7</sup>Princess Margaret Cancer Centre, Dept. of Surgical Oncology, Division of Urology, University Health Network, Toronto, Canada, <sup>8</sup>University Health Network, Dept. of Pathology, Toronto, Canada, <sup>9</sup>Group Hospitalier La Pitié-Salpêtrière, Université Pierre et Marie Curie, Dept. of Urology, Paris, France, <sup>10</sup>Group Hospitalier La Pitié-Salpêtrière, Université Pierre et Marie Curie, Dept. of Pathology, Paris, France

747

**Bladder cancer and seroreactivity to BK, JC and Merkel cell polyomaviruses: The Spanish bladder cancer study**

**By:** Garcia-Rojo D.<sup>1</sup>, Robles C.<sup>2</sup>, Viscidi R.<sup>3</sup>, Malats N.<sup>4</sup>, Silverman D.<sup>5</sup>, Gelabert-Mas A.<sup>6</sup>, Ibarz L.<sup>7</sup>, Cecchini L.<sup>6</sup>, Kogevinas M.<sup>8</sup>, Garcia-Closas R.<sup>9</sup>, Prera A.<sup>1</sup>, Lloreta J.<sup>10</sup>, Consol S.<sup>11</sup>, Carrato A.<sup>12</sup>, Abascal R.<sup>13</sup>, Fernandez J.M.<sup>13</sup>, Rodriguez De Vera J.M.<sup>14</sup>, Rivas M.<sup>15</sup>, Guate J.L.<sup>16</sup>, Malet J.M.<sup>17</sup>, Muntañola P.<sup>18</sup>, Gonzalez-Huergo J.<sup>19</sup>, Mosquera J.<sup>20</sup>, Cespedes M.<sup>21</sup>, Prats J.<sup>22</sup>, Real F.X.<sup>23</sup>

**Institutes:**<sup>1</sup>Consorci Hospitalari Parc Tauli, Dept. of Urology, Sabadell, Spain, <sup>2</sup>Catalan Institute of Oncology, Dept. of Infections and Cancer, Hospitalet De Llobregat, Spain, <sup>3</sup>Johns Hopkins University School of Medicine, Stanley Division of Developmental Neurovirology, Baltimore, United States of America, <sup>4</sup>Spanish National Cancer Research Centre (CNIO), Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, <sup>5</sup>National Cancer Institute, Dept. of Cancer Epidemiology and Genetics, Bethesda, United States of America, <sup>6</sup>Hospital Del Mar, Dept. of Urology, Barcelona, Spain, <sup>7</sup>Hospital Germans Trias I Pujol, Dept. of Urology, Badalona, Spain, <sup>8</sup>IMIM, Dept. of Epidemiology, Barcelona, Spain, <sup>9</sup>Hospital Universitario Canarias, Dept. of Epidemiology, Barcelona, Spain, <sup>10</sup>Hospital Del Mar, Dept. of Pathology, Barcelona, Spain, <sup>11</sup>Consorci Hospitalari Parc Tauli, Dept. of Epidemiology, Sabadell, Spain, <sup>12</sup>Hospital Elche, Dept. of Oncology, Elche, Spain, <sup>13</sup>Hospital Central De Asturias, Dept. of Urology, Oviedo, Spain, <sup>14</sup>Hospital Universitario De Canarias, Dept. of Urology, Santa Cruz de Tenerife, Spain, <sup>15</sup>Hospital Cabueñes, Dept. of Urology, Cabueñes, Spain, <sup>16</sup>Hospital Aviles, Dept. of Urology, Aviles, Spain, <sup>17</sup>Hospital Manresa, Dept. of Urology, Manresa, Spain, <sup>18</sup>Hospital Mieres, Dept. of Urology, Mieres, Spain, <sup>19</sup>Hospital Coaña, Dept. of Urology, Coaña, Spain, <sup>20</sup>Hospital Cangas, Dept. of Urology, Cangas, Spain, <sup>21</sup>Hospital Sant Boi, Dept. of Urology, Sant Boi De Llobregat, Spain, <sup>22</sup>Corporacio Parc Tauli, Dept. of Urology,

Sabadell, Spain, <sup>23</sup>Spanish National Cancer Research Centre (CNIO), Genetic and Molecular Epidemiology Group, Madrid, Spain

749 **Diagnostic utility of UroVysion for urothelial carcinoma of the upper urinary tract**

**By:** Sassa N.<sup>1</sup>, Tsuzuki T.<sup>2</sup>, Hattori R.<sup>3</sup>, Kato M.<sup>1</sup>, Ishida S.<sup>1</sup>, Sano T.<sup>3</sup>, Gotoh M.<sup>1</sup>

**Institutes:**<sup>1</sup>Nagoya University, Dept. of Urology, Nagoya, Japan, <sup>2</sup>Japanese Red Cross Nagoya Daini Hospital, Dept. of Pathology, Nagoya, Japan, <sup>3</sup>Japanese Red Cross Nagoya Daiichi Hospital, Dept. of Urology, Nagoya, Japan

750 **Detection of carcinoma in situ (CIS) of urinary bladder cancer using UBC® Rapid as tumour marker**

**By:** Ecke T.<sup>1</sup>, Arndt C.<sup>2</sup>, Gützlaff S.<sup>3</sup>, Stephan C.<sup>3</sup>, Lux O.<sup>1</sup>, Otto T.<sup>2</sup>, Hallmann S.<sup>1</sup>, Ruttloff J.<sup>1</sup>, Gerullis H.<sup>4</sup>

**Institutes:**<sup>1</sup>Helios Hospital, Dept. of Urology, Bad Saarow, Germany, <sup>2</sup>Lukaskrankenhaus, Dept. of Urology, Neuss, Germany, <sup>3</sup>University Hospital Charité, Dept. of Urology, Berlin, Germany, <sup>4</sup>University Oldenburg, Dept. of Urology, Oldenburg, Germany

751 **Colour and morphology combination for detection of low-grade urothelial cancer cells: Multi-center validation study**

**By:** Yossepowitch O.<sup>1</sup>, Leibovitch I.<sup>4</sup>, Nativ O.<sup>5</sup>, Cohen M.<sup>11</sup>, Mor Y.<sup>6</sup>, Lindner U.<sup>7</sup>, Sidi A.<sup>10</sup>, Matzkin H.<sup>9</sup>, Gofrit O.<sup>8</sup>, Rona R.<sup>12</sup>, Shtabsky A.<sup>2</sup>, Lew S.<sup>3</sup>

**Institutes:**<sup>1</sup>Rabin Medical Center, Dept. of Urology, Petach Tikva, Israel, <sup>2</sup>Sourasky Medical Center, Dept. of Pathology, Tel-Aviv, Israel, <sup>3</sup>Patho-Lab Diagnostics Ltd, Dept. of Pathology, Ness Ziona, Israel, <sup>4</sup>Meir Medical Center, Dept. of Urology, Kfar Saba, Israel, <sup>5</sup>Bnai Zion Medical Center, Dept. of Urology, Haifa, Israel, <sup>6</sup>Sheba Medical Center, Dept. of Urology, Tel-Aviv, Israel, <sup>7</sup>Kaplan Medical Center, Dept. of Urology, Rehovot, Israel, <sup>8</sup>Hadassah Medical Center, Dept. of Urology, Jerusalem, Israel, <sup>9</sup>Sourasky Medical Center, Dept. of Urology, Tel-Aviv, Israel, <sup>10</sup>Wolfson Medical Center, Dept. of Urology, Holon, Israel, <sup>11</sup>HaEmek Medical Center, Dept. of Urology, Afula, Israel, <sup>12</sup>Meir Medical Center, Dept. of Pathology, Kfar Saba, Israel